Table 1.
Baseline characteristics, one and 2 year outcomes, VA - visual acuity, CI - 95% CI.
| Baseline characteristics | One-year outcomes | Two-year outcomes | ||||
| Full cohort | One year only completers | One year vs 2 year completers | Two-year completers | |||
| Number of eyes/patients | 3357 | 3357 | 1601 | 1756 | 2177 | |
| Mean baseline age (years) (95% CI) | 78 (77.7 to 78.3) | 78 (77.7 to 78.3) | 79 (78.7 to 79.3) | P<0.001 | 77 (76.6 to 77.4) | 77 (76.6 to 77.4) |
| Gender female/male | 61/39 | 61/39 | 61/39 | 61/39 | 61/39 | |
| Mean baseline VA (letters) (95% CI) | 56.2 (55.6 to 56.8) | 56.2 (55.6 to 56.8) | 54.4 (53.8 to 55.0) | P<0.001 | 57.9 (57.2 to 58.6) | 57.8 (57.1 to 58.5) |
| Mean VA (letters) (95% CI) | 56.2 (55.6 to 56.8) | 61.8 (61.2 to 62.4) | 58.5 (57.9 to 59.1) | P<0.001 | 64.8 (64.1 to 65.5) | 62.7 (62.0 to 63.4) |
| Mean change in VA (letters) (95% CI) | 5.5 (5.0 to 6.0) | 4.1 (3.6 to 4.6) | P<0.001 | 6.8 6.1 to 7.5) | 4.9 (4.2 to 5.6) | |
| % of eyes gaining≥5 letters | 54% | 51% | P<0.001 | 58% | 54% | |
| % of eyes with stable vision (±<15 letters) | 66% | 65% | P=0.378 | 66% | 63% | |
| % of eyes with good VA (≥20/40) | 24% | 42% | 35% | P<0.001 | 49% | 44% |
| % of eyes with poor VA (≤20/200) | 17% | 11% | 16% | P<0.001 | 6% | 10% |
| Mean injection number (95% CI) over time | 7.7 (7.6 to 7.8) | 7.5 (7.4 to 7.6) | P<0.001 | 8.0 (7.8 to 8.2) | 13.0 (12.8 to 13.2) | |
Distribution of data was tested by the Shapiro-Wilk normality test. Means of non-parametric, paired groups were compared using Wilcoxon signed-rank test.